Following recent industry shifts, a former senior cell and gene therapy regulator from the FDA has joined Eli Lilly in a strategic policy role focused on the same therapeutic area. Simultaneously, Novo Nordisk appointed a new global research vice president as layoffs continue to shape its organizational landscape. These moves reflect evolving leadership dynamics in biopharma amid competitive and regulatory pressures.